Skip to main content

Vitamin A

Vitamin A (retinol) is an essential fat-soluble micronutrient that serves as a cofactor for vision, immune function, cellular differentiation, reproduction, and embryogenesis.[1][2] It is required by virtually every organ system, functioning through nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs) that regulate gene expression in > 500 genes.[3] Globally, an estimated 190 million preschool-aged children and 19 million pregnant women are affected by vitamin A deficiency.[4]

For the reconstructive urologist and urogynecologist, vitamin A matters in three high-yield ways: (1) the chronic-corticosteroid patient with delayed wound healing — vitamin A is the classic surgical recovery agent that reverses steroid-impaired epithelialization; (2) post-bariatric trace surveillance before later reconstruction (especially BPD/DS, RYGB); and (3) teratogenicity counseling in any reproductive-age patient on isotretinoin or high-dose vitamin A undergoing urogyn or reproductive-tract reconstruction.

Biochemistry and Metabolism​

"Vitamin A" encompasses a family of fat-soluble retinoid compounds:[1][3]

  • Preformed vitamin A (retinol, retinal, retinoic acid, retinyl esters) — Found exclusively in animal-source foods. Retinyl esters are hydrolyzed to retinol in the intestine, absorbed with dietary fat, and transported to the liver via chylomicrons.
  • Provitamin A carotenoids (β-carotene, α-carotene, β-cryptoxanthin) — Plant-derived pigments enzymatically cleaved to retinal in the intestine. β-carotene has the highest provitamin A activity, but the intestinal conversion ratio varies widely (6:1 to 26:1 by weight depending on food matrix), so plant sources alone may not provide adequate vitamin A.[5]

The liver stores 80–90% of total body vitamin A as retinyl esters within hepatic stellate cells (HSCs).[6][7] When needed, retinyl esters are hydrolyzed to retinol, which is released bound to retinol-binding protein (RBP) for delivery to target tissues. Sufficient hepatic stores can maintain requirements for months to years.[8][4]

Three active metabolites mediate vitamin A's biological functions:[1][3]

  • Retinal (retinaldehyde) — Essential for vision; 11-cis-retinal is the chromophore in rhodopsin and cone opsins.
  • Retinoic acid (all-trans and 9-cis) — The primary transcriptionally active form; binds RAR/RXR nuclear receptors to regulate cell differentiation, proliferation, apoptosis, and immune function.
  • Retinol — The transport and storage form; also has direct roles in reproduction and embryogenesis.

Dietary Sources and Requirements​

Preformed vitamin A is found in liver, fish oils, dairy products, and eggs, constituting 65–75% of dietary intake in Western diets. Provitamin A carotenoids are found in dark green leafy vegetables, carrots, sweet potatoes, mangoes, and red palm oil.[1][3][8]

PopulationRDA (μg RAE/day)UL (μg/day preformed)
Adult men9003,000 (~ 10,000 IU)
Adult women7003,000 (~ 10,000 IU)
Pregnant women7703,000
Lactating women1,3003,000
Children 1–3 years300600
Children 4–8 years400900

Dietary fat is required for absorption; low-fat diets and intestinal infections impair vitamin A uptake.[8]

Assessment of Vitamin A Status​

Assessing vitamin A status is challenging because serum retinol is homeostatically regulated across a wide range of liver stores and only declines when hepatic reserves are critically depleted.[4][9]

  • Serum retinol — Most commonly used biomarker. WHO cutoffs: deficiency < 0.70 μmol/L (20 μg/dL); severe deficiency < 0.35 μmol/L (10 μg/dL).[4][10]
  • Confounders — Lowered by infection, inflammation, hypoproteinemia, oral contraceptives, and pregnancy; elevated by hyperproteinemia and dehydration. As with albumin and zinc, inflammation significantly reduces measured levels independent of true stores.[4][11]
  • Retinol-binding protein (RBP) — Less expensive alternative to serum retinol; correlates well at population level but shares the same homeostatic and inflammatory limitations.[4]
  • Liver biopsy and retinol isotope dilution — Gold-standard reference tests for total body vitamin A stores, but impractical for routine use.[4][9]
  • Clinical assessment — Night blindness (earliest sign), Bitot's spots, conjunctival xerosis, corneal xerosis, keratomalacia — progressive stages of xerophthalmia, diagnostic of clinical deficiency.[4][12]

Causes of Deficiency​

CategoryExamples
Dietary insufficiencyLow intake of animal-source foods, poverty, plant-based diets with low-bioavailability sources
MalabsorptionCeliac disease, IBD, chronic pancreatitis, cystic fibrosis, short bowel syndrome, bariatric surgery (especially BPD/DS, RYGB)
Liver diseaseCirrhosis, alcoholic liver disease (impaired storage and RBP synthesis)
Increased demandPregnancy (especially third trimester), lactation, rapid growth in infancy
InfectionsMeasles, diarrheal illness, HIV (increased catabolism and urinary losses)

Clinical Manifestations of Deficiency​

Ocular — Hallmark of vitamin A deficiency is xerophthalmia, a spectrum of progressive eye disease:[4][8]

  1. Night blindness (nyctalopia) — Earliest symptom; impaired dark adaptation from insufficient 11-cis-retinal for rhodopsin regeneration.
  2. Conjunctival xerosis — Drying and keratinization of the conjunctiva.
  3. Bitot's spots — Triangular, foamy, keratinized deposits on bulbar conjunctiva; pathognomonic.
  4. Corneal xerosis — Drying and haziness of the cornea.
  5. Corneal ulceration / keratomalacia — Liquefactive necrosis of the cornea; medical emergency that can lead to permanent blindness.

Globally, vitamin A deficiency causes an estimated 250,000–500,000 children to become blind annually, with more than 50% dying within two years of losing sight.[13][4]

Immune — Deficiency impairs both innate and adaptive immunity — epithelial barrier integrity, neutrophil function, NK-cell activity, T-cell differentiation. Increased susceptibility to measles, diarrheal diseases, respiratory infections.[2][14]

Other — Growth retardation, impaired hematopoiesis (anemia), follicular hyperkeratosis, increased childhood mortality.[8][2]

Clinical Applications​

Childhood Mortality and Measles​

Vitamin A supplementation in children 6–59 months in deficiency-endemic areas is one of the most cost-effective public health interventions. A meta-analysis of 43 RCTs (~ 215,633 children) demonstrated a 24% reduction in all-cause mortality (RR 0.76, 95% CI 0.69–0.83), 28% reduction in diarrhea-related mortality, and 50% reduction in measles incidence.[14][15]

WHO and AAP recommend vitamin A for all children with measles, regardless of country of residence or disease severity. Age-specific dosing:[16][17]

  • < 6 months — 50,000 IU once daily × 2 days.
  • 6–11 months — 100,000 IU once daily × 2 days.
  • ≥ 12 months — 200,000 IU once daily × 2 days.

Vitamin A reduced measles mortality by 34–50% in large-scale RCTs.[16][17]

Retinoids in Dermatology​

Vitamin A derivatives are among the most widely used pharmacologic agents in dermatology:[18][19]

  • Isotretinoin (oral) — Disease-modifying treatment for severe nodulocystic acne; suppresses sebum, normalizes keratinization, modulates innate immunity. Teratogenic (see Safety below).
  • Tretinoin, adapalene, tazarotene, trifarotene (topical) — First-line for acne; also used for photoaging and melasma.
  • Acitretin (oral) — Psoriasis, pityriasis rubra pilaris, Darier disease, ichthyoses.
  • Bexarotene (oral / topical) — Cutaneous T-cell lymphoma.

Retinoids in Oncology​

All-trans retinoic acid (ATRA) revolutionized acute promyelocytic leukemia (APL) treatment, the first successful differentiation therapy in oncology. ATRA induces terminal differentiation of leukemic promyelocytes by degrading the PML-RARα fusion oncoprotein. Combined with arsenic trioxide ± chemotherapy, ATRA-based regimens achieve complete remission rates > 90% and cure rates ~ 80%.[20] 13-cis-retinoic acid is also used as maintenance therapy in high-risk neuroblastoma.

Treatment of Vitamin A Deficiency​

For clinical deficiency with xerophthalmia (medical emergency):[4][11][21]

  • Adults (parenteral) — 100,000 IU IM daily × 3 days, then 50,000 IU daily × 2 weeks, followed by oral multivitamin containing 10,000–20,000 IU daily × 2 months.[21]
  • Adults (oral, without corneal changes) — 10,000–25,000 IU daily × 1–2 weeks.[11]
  • With corneal lesions — 50,000–100,000 IU IM, then 50,000 IU IM daily × 2 weeks.[11]
  • Children — WHO-recommended high-dose supplementation (100,000–200,000 IU depending on age) for at-risk populations, every 4–6 months.[4]

Post-bariatric surgery — Standard multivitamins containing 5,000 IU may be insufficient; 10,000 IU daily of retinol acetate has been shown to be more effective in preventing deficiency after RYGB.[11]

Toxicity (Hypervitaminosis A)​

Unlike water-soluble vitamins, preformed vitamin A accumulates in the liver. β-carotene does not cause hypervitaminosis A (excess is stored harmlessly as carotenodermia).[14][22]

Acute toxicity (single dose > 25,000 IU/kg in adults, > 350,000 IU in infants) — Headache, nausea, vomiting, papilledema, bulging fontanelle in infants. Usually transient and reversible.[21][14]

Chronic toxicity (> 10,000 IU/day for prolonged periods) — Retinoid accumulation in HSCs drives steatosis → perisinusoidal fibrosis → cirrhosis.[10] Additional manifestations:[10][21][23]

  • Hepatic — Hepatomegaly, hepatotoxicity, jaundice.
  • Skeletal — Reduced BMD, increased hip fracture risk, premature epiphyseal closure in children.
  • CNS — Pseudotumor cerebri, headache.
  • Dermatologic — Dry / cracking skin, alopecia, lip fissures, desquamation.
  • Metabolic — Hypercalcemia (PTH-independent, from bone resorption) — vitamin A toxicity belongs in the differential of unexplained PTH-independent hypercalcemia.[24]

Patients with liver disease, hyperlipidemia, high alcohol intake, the elderly, children, and women of childbearing age are at increased toxicity risk.[23][25]

Teratogenicity — A Critical Safety Concern​

Preformed vitamin A (retinol and retinoic acid) is a potent teratogen, particularly during the first 60 days post-conception.[8][26] Retinoic acid embryopathy affects cranial neural crest cell migration and is characterized by malformations of:[27][28]

  • Craniofacial (cleft palate, micrognathia)
  • CNS (microcephaly, hydrocephalus)
  • Cardiovascular (conotruncal defects)
  • Thymic structures

A landmark NEJM study of > 22,000 pregnant women found an apparent teratogenic threshold near 10,000 IU/day of preformed vitamin A from supplements.[26] The WHO considers daily doses up to 10,000 IU (3,000 μg retinol) or 25,000 IU weekly after day 60 of gestation to be probably safe in deficient areas.[8]

Isotretinoin carries a ~ 26% risk of retinoic acid embryopathy with in utero exposure and a ~ 20% risk of spontaneous abortion.[27][29] The iPLEDGE program in the US mandates monthly pregnancy testing and dual contraception for females of childbearing potential.[29]

Vitamin A and Liver Disease​

The liver is the central organ for vitamin A metabolism. HSCs store 80% of total body retinol as retinyl esters within lipid droplets.[6][30][7] Upon liver injury, HSCs become activated, lose their retinol stores, and transdifferentiate into myofibroblast-like cells that produce extracellular matrix — the central mechanism of hepatic fibrosis.[6][30][31] This creates a paradox: liver disease depletes vitamin A stores (contributing to deficiency), while exogenous vitamin A supplementation in patients with existing liver disease can accelerate hepatotoxicity and fibrosis.[10][25]

Reconstructive Relevance​

1. The Chronic-Corticosteroid Patient — The Classic Surgical Pearl​

Corticosteroids inhibit wound healing by suppressing macrophage activity, fibroblast proliferation, and epithelialization. Vitamin A reverses this effect — first demonstrated by Hunt in 1969 — and remains the surgical recovery agent for the steroid-using patient facing elective reconstruction:

  • Indication — Chronic corticosteroid use (autoimmune disease, transplant, post-cancer, IBD, vasculitis) facing major reconstruction (urethroplasty, urinary diversion, complex prolapse, GAS, BMG-graft procedures, fistula repair).
  • Regimen — 25,000 IU oral vitamin A daily for 7–10 days perioperatively is the classic dose; topical vitamin A (retinol cream, 25,000–50,000 IU/oz) can be used on the wound for additional local effect.
  • Stop if active corticosteroid-dependent disease flares — vitamin A may counteract intended steroid effect; coordinate with prescribing clinician.
  • Do not use chronically — limit to perioperative window; long-term use risks hepatotoxicity.
  • Avoid in pregnancy — see teratogenicity above.

2. Post-Bariatric Trace Surveillance Before Later Reconstruction​

Vitamin A deficiency is common after malabsorptive bariatric procedures, particularly BPD/DS (~ 50% deficiency) and RYGB (~ 8–11%). Standard multivitamins containing 5,000 IU are often insufficient; ASMBS recommends 10,000 IU/day retinol acetate in BPD/DS patients.[11] Verify status before any elective reconstruction in this population — particularly relevant if delayed wound healing, night blindness, or unexplained xerophthalmia are reported.

3. Teratogenicity Counseling in Reconstructive Practice​

For any reproductive-age patient undergoing urogyn, BMG-related, or reproductive-tract reconstruction who may be planning future pregnancy:

  • Patients on isotretinoin — Must remain on iPLEDGE protocol (monthly pregnancy testing + dual contraception); discontinue ≥ 1 month before conception attempt.
  • Patients on topical retinoids (tretinoin, adapalene) — Systemic absorption is minimal; generally considered low risk, but advise discontinuation in confirmed pregnancy.
  • High-dose vitamin A supplements (> 10,000 IU/day) — Advise discontinuation 1 month prior to conception attempt.

4. Chronic Wound Healing (Non-Steroid Context)​

Burn, pressure-ulcer, and diabetic-ulcer evidence supports both topical and oral vitamin A for chronic-wound healing in deficient patients. For chronic pelvic / perineal wounds (radiation cystitis sequelae, fistula tract wounds, perineal-reconstruction healing), check vitamin A status alongside zinc, albumin, and CRP in non-resolving wounds.

5. Cirrhotic Patients Facing Reconstruction​

Two paradoxes to be aware of:

  • Cirrhotic patients are frequently deficient (impaired storage, low RBP), but
  • Exogenous vitamin A supplementation can accelerate fibrosis via HSC activation.

Do not empirically supplement vitamin A in cirrhotic patients facing reconstruction without measured deficiency; if deficient, supplement at low doses with hepatology coordination.

See Also​

References​

1. Haider BA, Sharma R, Bhutta ZA. "Neonatal Vitamin A Supplementation for the Prevention of Mortality and Morbidity in Term Neonates in Low and Middle Income Countries." Cochrane Database of Systematic Reviews. 2017;2:CD006980. doi:10.1002/14651858.CD006980.pub3

2. Hombali AS, Solon JA, Venkatesh BT, Nair NS, Peña-Rosas JP. "Fortification of Staple Foods With Vitamin A for Vitamin A Deficiency." Cochrane Database of Systematic Reviews. 2019;5:CD010068. doi:10.1002/14651858.CD010068.pub2

3. Dommisch H, Kuzmanova D, Jönsson D, Grant M, Chapple I. "Effect of micronutrient malnutrition on periodontal disease and periodontal therapy." Periodontology 2000. 2018;78(1):129–153. doi:10.1111/prd.12233

4. Gannon BM, Huey SL, Mehta NH, et al. "Selected Laboratory-Based Biomarkers for Assessing Vitamin A Deficiency in at-Risk Individuals." Cochrane Database of Systematic Reviews. 2025;5:CD013742. doi:10.1002/14651858.CD013742.pub2

5. Allen LH. "Micronutrients — Assessment, Requirements, Deficiencies, and Interventions." The New England Journal of Medicine. 2025;392(10):1006–1016. doi:10.1056/NEJMra2314150

6. Haaker MW, Vaandrager AB, Helms JB. "Retinoids in Health and Disease: A Role for Hepatic Stellate Cells in Affecting Retinoid Levels." Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids. 2020;1865(6):158674. doi:10.1016/j.bbalip.2020.158674

7. Kamm DR, McCommis KS. "Hepatic Stellate Cells in Physiology and Pathology." The Journal of Physiology. 2022;600(8):1825–1837. doi:10.1113/JP281061

8. McCauley ME, van den Broek N, Dou L, Othman M. "Vitamin A Supplementation During Pregnancy for Maternal and Newborn Outcomes." Cochrane Database of Systematic Reviews. 2015;(10):CD008666. doi:10.1002/14651858.CD008666.pub3

9. Tanumihardjo SA. "Vitamin A: Biomarkers of Nutrition for Development." The American Journal of Clinical Nutrition. 2011;94(2):658S–665S. doi:10.3945/ajcn.110.005777

10. Pestalardo ML, Bevilacqua CS, Amante MF. "Vitamin A Toxicity and Hepatic Pathology: A Comprehensive Review." World Journal of Hepatology. 2025;17(8):107738. doi:10.4254/wjh.v17.i8.107738

11. Stein J, Stier C, Raab H, Weiner R. "Review article: the nutritional and pharmacological consequences of obesity surgery." Alimentary Pharmacology & Therapeutics. 2014;40(6):582–609. doi:10.1111/apt.12872

12. Sahile Z, Yilma D, Tezera R, et al. "Prevalence of Vitamin A Deficiency among Preschool Children in Ethiopia: A Systematic Review and Meta-Analysis." BioMed Research International. 2020;2020:8032894. doi:10.1155/2020/8032894

13. Bello S, Meremikwu MM, Ejemot-Nwadiaro RI, Oduwole O. "Routine Vitamin A Supplementation for the Prevention of Blindness Due to Measles Infection in Children." Cochrane Database of Systematic Reviews. 2016;(8):CD007719. doi:10.1002/14651858.CD007719.pub4

14. Imdad A, Mayo-Wilson E, Haykal MR, et al. "Vitamin A Supplementation for Preventing Morbidity and Mortality in Children From Six Months to Five Years of Age." Cochrane Database of Systematic Reviews. 2022;3:CD008524. doi:10.1002/14651858.CD008524.pub4

15. Mayo-Wilson E, Imdad A, Herzer K, Yakoob MY, Bhutta ZA. "Vitamin A Supplements for Preventing Mortality, Illness, and Blindness in Children Aged Under 5: Systematic Review and Meta-Analysis." BMJ. 2011;343:d5094. doi:10.1136/bmj.d5094

16. Strebel PM, Orenstein WA. "Measles." The New England Journal of Medicine. 2019;381(4):349–357. doi:10.1056/NEJMcp1905181

17. Do LAH, Mulholland K. "Measles 2025." The New England Journal of Medicine. 2025;393(24):2447–2458. doi:10.1056/NEJMra2504516

18. Dessinioti C, Katsambas A. "Vitamins and the Skin: Vitamin A and Retinoids in Dermatology." Clinics in Dermatology. 2026;44(2):212–222. doi:10.1016/j.clindermatol.2026.02.005

19. Beckenbach L, Baron JM, Merk HF, Löffler H, Amann PM. "Retinoid Treatment of Skin Diseases." European Journal of Dermatology. 2015;25(5):384–391. doi:10.1684/ejd.2015.2544

20. Orfali N, McKenna SL, Cahill MR, Gudas LJ, Mongan NP. "Retinoid Receptor Signaling and Autophagy in Acute Promyelocytic Leukemia." Experimental Cell Research. 2014;324(1):1–12. doi:10.1016/j.yexcr.2014.03.018

21. Food and Drug Administration. "AQUASOL A Parenteral." Label updated 2026-03-03.

22. Bendich A, Langseth L. "Safety of Vitamin A." The American Journal of Clinical Nutrition. 1989;49(2):358–371. doi:10.1093/ajcn/49.2.358

23. Jain N, Maguire MG, Flaxel CJ, et al. "Dietary Supplementation for Retinitis Pigmentosa: A Report by the American Academy of Ophthalmology." Ophthalmology. 2025;132(3):354–367. doi:10.1016/j.ophtha.2024.09.004

24. Borgan SM, Khan LZ, Makin V. "Hypercalcemia and Vitamin A: A Vitamin to Keep in Mind." Cleveland Clinic Journal of Medicine. 2022;89(2):99–105. doi:10.3949/ccjm.89a.21056

25. Bartlett H, Eperjesi F. "Possible Contraindications and Adverse Reactions Associated With the Use of Ocular Nutritional Supplements." Ophthalmic & Physiological Optics. 2005;25(3):179–194. doi:10.1111/j.1475-1313.2005.00294.x

26. Rothman KJ, Moore LL, Singer MR, et al. "Teratogenicity of High Vitamin A Intake." The New England Journal of Medicine. 1995;333(21):1369–1373. doi:10.1056/NEJM199511233332101

27. Hughes JE, Buckley N, Looney Y, et al. "Evaluating awareness, knowledge and practice of healthcare professionals following implementation of a revised pregnancy prevention programme for isotretinoin in Ireland." Pharmacoepidemiology and Drug Safety. 2023;32(2):137–147. doi:10.1002/pds.5538

28. Gheysen W, Kennedy D. "An update on maternal medication-related embryopathies." Prenatal Diagnosis. 2020;40(9):1168–1177. doi:10.1002/pd.5764

29. Tkachenko E, Singer S, Sharma P, Barbieri J, Mostaghimi A. "US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated With Isotretinoin." JAMA Dermatology. 2019;155(10):1175–1179. doi:10.1001/jamadermatol.2019.1388

30. Lee YS, Jeong WI. "Retinoic Acids and Hepatic Stellate Cells in Liver Disease." Journal of Gastroenterology and Hepatology. 2012;27(Suppl 2):75–79. doi:10.1111/j.1440-1746.2011.07007.x

31. Yoneda A, Sakai-Sawada K, Niitsu Y, Tamura Y. "Vitamin A and Insulin Are Required for the Maintenance of Hepatic Stellate Cell Quiescence." Experimental Cell Research. 2016;341(1):8–17. doi:10.1016/j.yexcr.2016.01.012